211096-49-0
中文名稱(chēng)
化合物SB-265610
英文名稱(chēng)
GSK-CXCR2
CAS
211096-49-0
分子式
C14H9BrN6O
分子量
357.16
MOL 文件
211096-49-0.mol
更新日期
2024/12/24 22:25:08
211096-49-0 結(jié)構(gòu)式
基本信息
中文別名
化合物SB-265610 英文別名
GSK-CXCR2SB 265610
SB265610 >=98% (HPLC)
N-(2-Bromophenyl)-N'-(7-cyano-1H-benzotriazol-4-yl)urea
Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-benzotriazol-7-yl)-
1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d] [1,2,3]triazol-7-yl)urea
CXCR,nonpeptide,inhibit,Inhibitor,SB-265610,inflammation,recruitment,Delay,SB 265610,healing,neutrophil,SB265610,wound,CXC chemokine receptors
所屬類(lèi)別
生物：拮抗劑安全數(shù)據(jù)
常見(jiàn)問(wèn)題列表
生物活性
SB-265610 是一種選擇性的競(jìng)爭(zhēng)性非肽變構(gòu) CXCR2 拮抗劑。SB-265610 阻斷大鼠 CINC-1 誘導(dǎo)的鈣動(dòng)員和中性粒細(xì)胞趨化性，IC50 分別為 3.7 nM 和 70 nM。靶點(diǎn)
|
CXCR2
|
體外研究
In vitro, SB-265610 antagonizes rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization, IC 50 of 3.7 nM, and rat neutrophil chemotaxis in a concentration-dependent manner, IC 50 of 70 nM. SB-265610 reduces the antiapoptotic effect of CINC-1 to the levels of those untreated with CINC-1.
體內(nèi)研究
SB-265610 (100 mg/kg/day; oral administration; daily; for 5 days; CXCR2 wild type mice) treatment during the wound repair process markedly delays healing parameters in CXCR2 wild type mice.
| Animal Model: | Wild type mice with nitrogen mustard |
| Dosage: | 100 mg/kg/day |
| Administration: | Oral administration; daily; for 5 days |
| Result: | Markedly impaired the wound healing process. |